Список проголосовавших за комментарий " On The Wires<ul><li>Soligenix (<strong>SNGX</strong>) will present results from its ricin toxin vaccine development program at the Society of Toxicology 56th Annual Meeting on March 12-16, 2017. The poster presentation focuses on the further optimization of the primate ricin challenge model that is important to facilitating future approval of RiVax under the FDA «Animal Rule».</li><li>Kratos Defense & Security Solutions, Inc. (<strong>KTOS</strong>) announced today that its Microwave Electronics Division recently received $13.7 million in contract awards related to specialized communication systems. MED is a leading provider of integrated microwave assemblies, solid state power amplifiers, GPS immune modules and other microwave electronic products that support radar, missile, electronic warfare, guidance, unmanned aerial and other systems. Work under these contract awards will be produced in a secure Kratos manufacturing facility. Due to customer related and other considerations, no additional information is being provided related to these contract awards.</li><li>Alkermes (<strong>ALKS</strong>) in a regulatory filing confirmed that on March 9, 2017, the United States Patent and Trademark Office Patent Trials and Appeal Board upheld the claims challenged via the inter partes review process of U.S. Patent Nos. 8,663,685, 8,440,703, 8,354,437 and 8,007,826, which are Orange Book-listed patents for Acorda's (ACOR) AMPYRA (dalfampridine) Extended Release Tablets, 10 mg. These patents, as well as U.S. Patent No. 5,540,938, which was not involved in the IPR Proceeding and is also an AMPYRA Orange Book-listed patent, have also been challenged in the U.S. District Court for the District of Delaware. The Court has completed the trial of the case, but not yet issued its decision.</li></ul>"